An Innovative Solution
TRIDENT, a one-stop-shop platform that combines three models, is being
developed to validate a novel pre-clinical approach. TRIDENT will standardize the use of brain imaging and humanized cognitive behavioral testing in animal models. Furthermore, by implementing sex-based assessment and testing at multiple sites, TRIDENT will dramatically improve the odds of success in clinical trials by de-risking the neurotherapeutics at the very earliest stage possible, i.e., at pre-clinical testing.
$92.8B
The estimated annual healthcare costs for Canadians affected by dementia alone by 2031 according to the Public Health Agency of Canada.
$1B
The required total for a neurotherapeutic to progress to regulatory market submission.
$50M
The current cost to bring a single compound to clinical trials.
90%
The percentage of research and development costs associated with late-stage trial failures.
Drug Development. Faster and Cheaper.
The TRIDENT platform will provide expert validation of proposed neurotherapeutics using 3 integrated model systems modalities of biomarkers with Sex Based Analysis, Open Science, and impartial decision-making embedded throughout.
TRIDENT aims to close the gap across the “valley of death” – the crucial phase between pre-clinical lab testing and human trials of drugs and their subsequent commercialization, where most compounds fail.
By leading real and lasting change in the way therapies are tested for neurodegenerative disorders, TRIDENT will dramatically improve their chances of success in clinical trials, benefiting millions of patients worldwide.
Organoids are used as starting models to assess pathophysiology and to evaluate the efficacy of neurotherapeutic
Humanized mouse models are the next stage in validating the efficacy of
neurotherapeutics. Using human-relevant translational metrics, molecular,
cognitive, and imaging biomarkers will be thoroughly assessed to determine
efficacy.
Identical cognitive, imaging and molecular approaches are studied using marmosets, models with close phylogenetic proximity and genetic similarity to humans.
A therapeutic that has been evaluated by our team of experts via the TRIDENT pipeline will receive a robust recommendation for success in human trials.
